To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
NCT ID: NCT06646354
Last Updated: 2025-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE3
125 participants
INTERVENTIONAL
2025-04-22
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
NCT06212648
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
NCT06441630
Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan
NCT03231982
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT03226340
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
NCT02944734
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is multi-center, double-blind, Active-controlled, parallel-group, phase 3 study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HODO-2224-1+HODO-2224-2+HODO-2224-4
Oral tablet, QD
Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
PO, QD, 8 weeks
HODO-2224-1+HODO-2224-4+HODO-2224-5
Oral tablet, QD
Candesartan/Amlodipine
PO, QD, 8 weeks
HODO-2224-2+HODO-2224-3+HODO-2224-6
Oral tablet, QD
Candesartan/Rosuvastatin/Ezetimibe
PO, QD, 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
PO, QD, 8 weeks
Candesartan/Amlodipine
PO, QD, 8 weeks
Candesartan/Rosuvastatin/Ezetimibe
PO, QD, 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with Essential Hypertension and Primary Hypercholesterolemia
Exclusion Criteria
* Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hyundai Pharm
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD_CARE_002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.